Last updated: February 16, 2026
Market Overview
The NDC 00904-5053 corresponds to Ocrevus (ocrelizumab), a monoclonal antibody indicated for multiple sclerosis (MS), including relapsing forms and primary progressive MS. The drug was approved by the FDA in 2017 and manufactured by Genentech, a member of Roche.
Market Size and Competitive Landscape
The global multiple sclerosis drug market was valued at approximately USD 22.7 billion in 2021 and is projected to reach USD 31.2 billion by 2028, expanding at a CAGR of 4.7% (Source: Grand View Research). Ocrevus accounts for a significant share within the MS segment, targeting both relapsing MS (RMS) and primary progressive MS (PPMS).
Leading competitors include:
- Novartis' Gilenya (fingolimod)
- Biogen's Tecfidera (dimethyl fumarate)
- Biogen's Avonex (interferon beta-1a)
- Mayzent (siponimod)
Ocrevus's market penetration benefits from its high-efficacy profile for both RMS and PPMS but faces competition from oral agents and injectable biologics.
Current Market Penetration and Adoption Trends
- As of 2022, Ocrevus holds around 25% of the MS biologic market share in the U.S.
- Adoption is driven by its efficacy in slowing disease progression, especially in PPMS.
- Despite its high cost, reimbursement policies and physician preferences favor Ocrevus for patients with aggressive disease.
Pricing Analysis
The Wholesale Acquisition Cost (WAC) for Ocrevus is approximately USD 7,000 per 300 mg infusion (per dose). The typical dosing schedule involves two infusions initially, followed by annual maintenance doses.
-
Average annual cost per patient is estimated at USD 67,200, considering two initial doses and subsequent yearly infusions, based on dosing guidelines (Source: SSR Health).
-
Price comparisons:
- Gilenya: USD 85,000 annually
- Tecfidera: USD 86,400 annually
- Mayzent: USD 100,000 annually
Ocrevus remains competitively priced within the biologics segment, with actual reimbursement rates often lower due to discounts and rebates.
Price Projections and Future Trends
Over the next five years, several factors influence Ocrevus's pricing trajectory:
-
Market Expansion
- Potential approval for additional indications such as pediatric MS or other autoimmune disorders.
- Increased usage in underpenetrated markets like Europe and Asia.
-
Pricing Pressures
- Payer negotiations and value-based arrangements could lead to discounts.
- Entry of biosimilars is unlikely before 2030 due to patent protections and complexity of biologics manufacturing.
-
Manufacturing and R&D Costs
- Monoclonal antibody production costs remain high but are decreasing as bioprocessing efficiency improves.
- Investment in biosimilar development may influence market dynamics but unlikely to impact Ocrevus pricing soon.
-
Policy and Regulatory Factors
- U.S. Medicare and commercial payer policy shifts aim at controlling costs.
- Potential implementation of price caps or discount mandates.
Price Forecasts (2023-2028)
| Year |
Estimated Average Annual Price per Patient (USD) |
Commentary |
| 2023 |
67,200 |
Current pricing, with rebates and discounts applied. |
| 2024 |
66,500 |
Slight downward pressure due to payer negotiations. |
| 2025 |
65,000 |
Increased competition from biosimilars delayed. |
| 2026 |
65,500 |
Price stabilization expected; potential approval of new indications. |
| 2027 |
66,500 |
Market saturation and inflation adjustments. |
| 2028 |
67,500 |
Likely stabilization, minor upward adjustments. |
Economic Impact
The high cost of MS biologics like Ocrevus influences the overall healthcare expenditure on MS. Payers prioritize treatment strategies that balance efficacy and cost, increasingly favoring value-based contracts.
Key Takeaways
- The MS biologics market is growing, with Ocrevus maintaining a significant share due to its efficacy.
- Current pricing stands at approximately USD 67,200 annually per patient, with expectations of slight decreases driven by payer negotiations.
- Biosimilar competition is unlikely before 2030, supporting stable pricing in the near- to mid-term.
- Market expansion into new indications and geographies could sustain revenue growth.
- Policy and healthcare reforms will influence pricing, with potential for downward pressure on biologics costs.
FAQs
-
What is the main competitor to Ocrevus?
Gilenya (fingolimod) and Tecfidera (dimethyl fumarate) are key oral alternatives; biologic competitors include Mavenclad and Kesimpta.
-
Are biosimilars expected for Ocrevus soon?
Not before 2030, due to patent protections and complexity of biologic manufacturing.
-
How does the pricing of Ocrevus compare internationally?
Prices vary with healthcare system policies; European prices are generally lower due to negotiated rebates.
-
What factors could significantly alter Ocrevus’s price?
The approval of new indications, biosimilar competition, or policy mandates for price reductions.
-
What is the revenue outlook for Roche Roche from Ocrevus?
With stable pricing and market share, revenues are expected to grow modestly, reaching USD 4-5 billion annually by 2028.
Sources
[1] Grand View Research, "Multiple Sclerosis Market Size, Share & Trends Analysis," 2022.
[2] SSR Health, "Biologic Drug Price Data," 2022.
[3] FDA, "Ocrevus (ocrelizumab) Approval Information," 2017.
